SCHEMBL2831355

SCHEMBL2831355

COCCCn1c(C)c(C(=O)O)c2ccccc2c1=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.65
KMT2A Q03164 6/20 0.50
MEN1 O00255 5/20 0.50
ATM Q13315 2/20 0.45
KDM4E B2RXH2 3/20 0.44
HSD17B10 Q99714 2/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
PLK1 P53350 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
RAB9A P51151 2/20 0.43
HSP90AA1 P07900 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2832041 0.92 ALDH1A1 (0.52) ALDH1A1KMT2AMEN1ATMKDM4E
SCHEMBL2830643 0.85 TDP1 (0.62) ALDH1A1KMT2AMEN1KDM4EHSD17B10
SCHEMBL2835070 0.84 L3MBTL1 (0.56) ALDH1A1KMT2AMEN1TDP1L3MBTL1
SCHEMBL2834290 0.82 MEN1 (0.49) ALDH1A1KMT2AMEN1ATMKDM4E
SCHEMBL2154580 0.81 ALDH1A1 (0.51) ALDH1A1KMT2AMEN1ATMCYP1A2
SCHEMBL2834167 0.78 ALDH1A1 (0.63) ALDH1A1KMT2AMEN1ATMKDM4E
SCHEMBL2831869 0.78 MAPT (0.44) ALDH1A1KMT2AMEN1ATMKDM4E
SCHEMBL11391241 0.76 CNR2 (0.54) CYP1A2CYP2C19LMNAHPGDNPSR1
SCHEMBL3350444 0.76 SMN1; SMN2 (0.58) ALDH1A1KMT2AMEN1KDM4ERAB9A
SCHEMBL3491860 0.75 TDP1 (0.44) ALDH1A1KMT2AMEN1ATMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP claimed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US claimed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US claimed
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP disclosed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 ALDH1A1 2399/4885KMT2A 891/4885MEN1 2461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.